EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The challenge of introducing aldosterone synthase inhibitors into multidisciplinary practice

Lauren E Heath iD, Sunil V Badve, Jun Yang iD, Brendon L Neuen iD

American Journal of Hypertension · 2026

DOI: 10.1093/ajh/hpag074 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hypertension, 2026. Verfasst von Lauren E Heath und 3 weiteren Autor:innen. Beteiligte Einrichtung: The George Institute for Global Health, University of New South Wales, Sydney, Australia. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Antihypertensive Agents, Blood Pressure. Die Arbeit nennt 57 Literaturangaben. Gefördert von: National Health and Medical Research Council, Medical Research Future Fund, Ramaciotti Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel therapeutic agents are required to improve hypertension control globally, which remains one of the leading modifiable risk factors for premature cardiovascular mortality. Aldosterone synthase inhibitors (ASIs) are a novel class of agents that suppress aldosterone production and have demonstrated clinically meaningful blood pressure reductions in phase 2 and phase 3 trials in patients with uncontrolled and resistant hypertension. As these therapies approach clinical adoption, important questions remain regarding effects on cardiovascular and kidney outcomes, safety profile, and optimal positioning within existing treatment algorithms. This review synthesizes the current clinical evidence for ASIs, highlights key knowledge gaps, and examines practical considerations for their real-world implementation, including persistent pharmacodynamic effects after treatment withdrawal, short-term changes in glomerular filtration rate, the risk of hyperkalemia, and the potential role of multidisciplinary care models to support safe and effective adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionCytochrome P-450 CYP11B2Antihypertensive AgentsBlood PressureHumansTreatment OutcomeRenin-Angiotensin SystemDrug ResistanceAldosterone

Stichwörter der Autor:innen

aldosterone synthase inhibitorsblood pressurehypertensionimplementation sciencerenin angiotensin aldosterone systemresistant hypertension

Substanzen

Cytochrome P-450 CYP11B2Antihypertensive AgentsAldosterone

Autor:innen und Institutionen

  • The George Institute for Global Health, University of New South Wales, Sydney, Australia.
  • Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia.
  • Department of Renal Medicine, St. George Hospital, Sydney, Australia.
  • Centre for Endocrinology and Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
  • Department of Medicine, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Lauren E Heath, Jun Yang, Brendon L Neuen

Förderung

  • National Health and Medical Research Council
  • Medical Research Future Fund
  • Ramaciotti Foundation
  • New South Wales Health
  • AstraZeneca

Zitieren

APA

Heath, L. E., Badve, S. V., Yang, J., & Neuen, B. L. (2026). The challenge of introducing aldosterone synthase inhibitors into multidisciplinary practice. American Journal of Hypertension. https://doi.org/10.1093/ajh/hpag074

Vancouver

Heath LE, Badve SV, Yang J, Neuen BL. The challenge of introducing aldosterone synthase inhibitors into multidisciplinary practice. American Journal of Hypertension. 2026. doi:10.1093/ajh/hpag074

BibTeX
@article{Heath2026,
  author = {Heath, Lauren E and Badve, Sunil V and Yang, Jun and Neuen, Brendon L},
  title = {The challenge of introducing aldosterone synthase inhibitors into multidisciplinary practice},
  journal = {American Journal of Hypertension},
  year = {2026},
  doi = {10.1093/ajh/hpag074}
}
Kostenlos starten →